By Anna C. Greene, PhD, NETRF Chief Scientific Officer One of the most exciting developments in neuroendocrine cancer treatment in recent years has been the introduction of tarlatamab, a new immunotherapy. This drug is designed to help a patient’s immune system find and destroy cancer cells that express the DLL3 marker, a protein commonly found … Continue reading New Blood Test May Help Guide Neuroendocrine Cancer Therapy